Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Oncology Focusing On Genetic Drivers Of Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer’s latest refinement to its oncology R&D strategy includes an increased focus on personalized medicine, concentrating on biomarkers for patient selection and development of companion diagnostics.

You may also be interested in...

Pfizer Halts Sutent's Phase III in Hepatocellular Carcinoma

Failure is the second in two months for Sutent, which is a lynchpin of Pfizer's oncology strategy.

New Research Highlights Potential And Pitfalls Of BRAF Inhibitors

Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.

With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too

With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts